JPH09502730A - ニューロトロフィン誘導活性を高めるK−252a誘導体 - Google Patents
ニューロトロフィン誘導活性を高めるK−252a誘導体Info
- Publication number
- JPH09502730A JPH09502730A JP7509379A JP50937995A JPH09502730A JP H09502730 A JPH09502730 A JP H09502730A JP 7509379 A JP7509379 A JP 7509379A JP 50937995 A JP50937995 A JP 50937995A JP H09502730 A JPH09502730 A JP H09502730A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- neurotrophin
- cells
- trk
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ニューロトロフィン応答性細胞と、式: [式中、 a)Z1およびZ2は一緒になってOを表す; 各R1、R2、R5およびR6は、独立して、H、F、Cl、Br、I、NO2、C N、炭素数1-6のアルキル、または、各R13およびR14が、独立して、Hまた は炭素数1-6のn-アルキルであるNR13R14; YはH、OH、NH2、炭素数1-6のn-アルキル、CHO、OCONH2、ベ ンジル、炭素数1-6のO-n-アルキル、またはnが1-6の整数である(CH2)n OHもしくは(CH2)nNH2; 上記の場合には、 1)RはOH、OCONH2、または、炭素数1-6のO-n-アルキル; XはCH2OH、CH2NH2(またはその酸性塩)、炭素数2-7のCH2O-n-ア ルキル、R7がHまたは炭素数1-6のアルキルであるCO2R7、nが1-6の整 数であって、R8がHもしくはアシル誘導体基であるCONHOR8もしくはCO NH(CH2)nOR8、または、R9が炭素数1-3のアルキルであるCONHR9;ま たは、 2)RおよびXは、一緒になって、各R10およびR11が、独立して、Hまた は炭素数1-3のアルキルである式-CH2OCR10R11O;または、R12がH または炭素数1-3のアルキルである-CH2NR12CO2-で示される連結基を形 成する;のいずれかである; あるいは、 b)Z1はHであって、Z2はOH; YはHまたはCHO; RはOH;および XはCONH(CH2)2OH、CO2CH3またはCH2OH;および R1、R2、R5およびR6はa)の定義に同じ; あるいは、 c)Z1およびZ2は共にH;および YはH、CHO、炭素数1-6のn-アルキルまたはOCONH2; 上記の場合には、 1)RはOH、炭素数1-6のO-n-アルキルまたはOCONH2であり、但 し、YがHである場合、RはOH;および、XはCONHOR8、nが1-6の整 数であるCONH(CH2)nOR8、CH2OHまたはCO2CH3であり、但し、Y がHであって、R1、R2、R5およびR6が各々Hである場合、XはCO2CH3と はなり得ない;または 2)RおよびXは、一緒になって、式-CH2NR12CO2-で示される連結基 を形成する;各R1、R2、R5およびR6はa)の定義に同じ、但し、R1がBr である場合、XはCH2OHとはなり得ない;のいずれかである; あるいは、 d)Z1はHであって、Z2はR15が炭素数1-3のn-アルキルであるSR15; Y、RおよびXはb)の定義に同じであり、但し、R15がC2H5である場合、X はCH2OHとはなり得ず;かつ、R1、R2、R5およびR6はa)の定義に同じ ]で示されるK-252a誘導体とを接触させることを特徴とする該細胞のニュ ーロトロフィン-誘導活性を上昇させる方法。 2.ニューロトロフィン応答性細胞と、式: [式中: a)Z1およびZ2は一緒になってOを表す 上記の場合には 1)各R1、R2、R5およびR6は、独立して、H、F、Cl、Br、I、NO2 、CN、炭素数1-6のアルキル、または、各R13およびR14が、独立して、H または炭素数1-6のn-アルキルであるNR13R14;YはH、OH、NH2、炭 素数1-6のn-アルキル、CHO、ベンジル、炭素数1-6のO-n-アルキル、 nが1-6の整数である(CH2)nOHまたは(CH2)nNH2;各R3およびR4は、 独立して、Hまたはnが1-6の整数である(CH2)nCH(OH)CH2OH;また は 2)各R1、R2、R3、R4、R5およびR6は、独立して、H;Yはa)1) の定義に同じであり、但し、Yはベンジルとはなり得ない;のいずれかである; あるいは、 b)Z1はHであって、Z2はH、OHまたはR15が炭素数1-3のn-アルキル であるSR15; YはHまたはCHO;および 各R1、R2、R3、R4、R5、R6は、独立して、H] で示されるK-252a誘導体とを接触させることを特徴とする該細胞のニュー ロトロフィン-誘導活性を上昇させる方法。 3.ニューロトロフィン応答性細胞と、式: [式中: a)各P1およびP2はHであるか、またはP1およびP2は一緒になってO を表す; 各W1およびW2はHであるか、またはW1およびW2は一緒になってO を表す; 但し、各P1およびP2はW1およびW2とは異なる] で示されるK-252a誘導体とを接触させることを特徴とする該細胞のニュー ロトロフィン-誘導活性を上昇させる方法。 4.さらに、該細胞と外因性のニューロトロフィンとを接触させることよりなる 請求項1記載の方法。 5.該ニューロトロフィンがNT-3である請求項4記載の方法。 6.さらに、該細胞と外因性のニューロトロフィンとを接触させることよりなる 請求項2記載の方法。 7.該ニューロトロフィンがNT-3である請求項6記載の方法。 8.さらに、該細胞と外因性のニューロトロフィンとを接触させることよりなる 請求項3記載の方法。 9.該ニューロトロフィンがNT-3である請求項8記載の方法。 10.以下の式: によって表される化合物またはその医薬上許容される塩。 11.以下の式: によって表される化合物またはその医薬上許容される塩。 12.以下の式: によって表される化合物またはその医薬上許容される塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/122,893 US5468872A (en) | 1993-09-16 | 1993-09-16 | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
US08/122,893 | 1993-09-16 | ||
PCT/US1994/010495 WO1995007911A1 (en) | 1993-09-16 | 1994-09-16 | K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005127746A Division JP2005220141A (ja) | 1993-09-16 | 2005-04-26 | ニューロトロフィン誘導活性を高めるK−252a誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502730A true JPH09502730A (ja) | 1997-03-18 |
JP3943126B2 JP3943126B2 (ja) | 2007-07-11 |
Family
ID=22405467
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50937995A Expired - Fee Related JP3943126B2 (ja) | 1993-09-16 | 1994-09-16 | ニューロトロフィン誘導活性を高めるK−252a誘導体 |
JP2005127746A Pending JP2005220141A (ja) | 1993-09-16 | 2005-04-26 | ニューロトロフィン誘導活性を高めるK−252a誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005127746A Pending JP2005220141A (ja) | 1993-09-16 | 2005-04-26 | ニューロトロフィン誘導活性を高めるK−252a誘導体 |
Country Status (14)
Country | Link |
---|---|
US (2) | US5468872A (ja) |
EP (1) | EP0719268B1 (ja) |
JP (2) | JP3943126B2 (ja) |
KR (1) | KR100186912B1 (ja) |
AT (1) | ATE203751T1 (ja) |
AU (1) | AU693480B2 (ja) |
CA (1) | CA2171561C (ja) |
DE (1) | DE69427862T2 (ja) |
ES (1) | ES2160637T3 (ja) |
FI (1) | FI961236A (ja) |
HU (1) | HU222570B1 (ja) |
NO (1) | NO309228B1 (ja) |
NZ (2) | NZ274355A (ja) |
WO (1) | WO1995007911A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009544703A (ja) * | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
JP2012513447A (ja) * | 2008-12-22 | 2012-06-14 | クレアビリ ソスィエテ アノニム | インドロカルバゾール化合物のポリマー結合体の合成 |
US8932821B2 (en) | 2003-03-19 | 2015-01-13 | Biogen Idec Ma Inc. | NOGO receptor binding protein |
US9068992B2 (en) | 2004-06-24 | 2015-06-30 | Biogen Ma Inc. | Screening methods for identifying Sp35 antagonists |
US9066984B2 (en) | 2005-07-08 | 2015-06-30 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
US9745375B2 (en) | 2008-07-09 | 2017-08-29 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0610433A1 (en) * | 1991-11-08 | 1994-08-17 | The University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
CA2144940A1 (en) * | 1994-03-18 | 1995-09-19 | Chikara Murakata | Therapeutic agent for thrombocytopenia and indolocarbazole derivatives |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
WO1997005140A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Trindene compounds |
WO1997005141A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Staurosporine analogues |
US5808060A (en) * | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
US6875865B1 (en) | 1996-06-03 | 2005-04-05 | Cephalon, Inc. | Selected derivatives of K-252a |
UA67725C2 (en) | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
ES2194385T3 (es) | 1997-12-31 | 2003-11-16 | Cephalon Inc | Derivados del k-252a 3'-epimeros. |
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
US7795246B2 (en) * | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
ATE361752T1 (de) * | 1998-09-25 | 2007-06-15 | Cephalon Inc | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen |
WO2000075662A1 (en) * | 1999-06-09 | 2000-12-14 | Ljl Biosystems, Inc. | Cell-signaling assays |
WO2001010440A1 (en) * | 1999-08-09 | 2001-02-15 | Trustees Of Dartmouth College | COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS |
FR2798931B1 (fr) * | 1999-09-22 | 2001-11-16 | Oreal | Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture |
US7129250B2 (en) | 2000-05-19 | 2006-10-31 | Aegera Therapeutics Inc. | Neuroprotective and anti-proliferative compounds |
US6610727B2 (en) | 2000-10-06 | 2003-08-26 | Bristol-Myers Squibb Company | Anhydro sugar derivatives of indolocarbazoles |
US6653290B2 (en) | 2000-10-06 | 2003-11-25 | Bristol-Myers Squibb Company | Tumor proliferation inhibitors |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
US6555677B2 (en) * | 2000-10-31 | 2003-04-29 | Merck & Co., Inc. | Phase transfer catalyzed glycosidation of an indolocarbazole |
US6855698B2 (en) | 2001-03-22 | 2005-02-15 | Bristol-Myers Squibb Company | Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles |
AR035971A1 (es) * | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
US20040186044A1 (en) * | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
EP1891966B1 (en) | 2002-12-20 | 2012-02-15 | H. Lundbeck A/S | Modulation of activity of neurotrophins; screening method |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
SI3225251T1 (sl) | 2006-12-21 | 2020-03-31 | H. Lundbeck A/S | Modulacija aktivnosti pronevrotrofinov |
WO2009067221A2 (en) * | 2007-11-20 | 2009-05-28 | Cephalon, Inc. | Microemulsion containing indolocarbazole compound and dosage forms containing the same |
ES2326459B1 (es) | 2008-04-08 | 2010-05-28 | Universidad De Oviedo | Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos. |
CN103242404A (zh) * | 2012-02-03 | 2013-08-14 | 复旦大学 | N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途 |
CN103012417B (zh) * | 2013-01-08 | 2015-01-07 | 中国科学院昆明植物研究所 | 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60257652A (ja) * | 1984-06-02 | 1985-12-19 | Canon Inc | 画像処理装置 |
US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
JPH0826036B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US4735939A (en) * | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
US4923986A (en) * | 1987-03-09 | 1990-05-08 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance K-252 |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
DE3835842A1 (de) * | 1988-10-21 | 1990-04-26 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
AU2322392A (en) * | 1991-07-03 | 1993-02-11 | Regeneron Pharmaceuticals, Inc. | Method and assay system for neurotrophin activity |
EP0610433A1 (en) * | 1991-11-08 | 1994-08-17 | The University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
JPH05247056A (ja) * | 1992-03-03 | 1993-09-24 | Kyowa Hakko Kogyo Co Ltd | インドロカルバゾール誘導体 |
DE4217963A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Verwendung von Indolocarbazolen zur Behandlung von AIDS |
DE4217964A1 (de) * | 1992-05-30 | 1993-12-02 | Goedecke Ag | Indolocarbazol-Imide und deren Verwendung |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
-
1993
- 1993-09-16 US US08/122,893 patent/US5468872A/en not_active Expired - Lifetime
-
1994
- 1994-09-16 ES ES94929228T patent/ES2160637T3/es not_active Expired - Lifetime
- 1994-09-16 AT AT94929228T patent/ATE203751T1/de not_active IP Right Cessation
- 1994-09-16 HU HU9600657A patent/HU222570B1/hu not_active IP Right Cessation
- 1994-09-16 US US08/307,530 patent/US5516772A/en not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010495 patent/WO1995007911A1/en active IP Right Grant
- 1994-09-16 EP EP94929228A patent/EP0719268B1/en not_active Expired - Lifetime
- 1994-09-16 KR KR1019960701361A patent/KR100186912B1/ko not_active IP Right Cessation
- 1994-09-16 NZ NZ274355A patent/NZ274355A/en not_active IP Right Cessation
- 1994-09-16 DE DE69427862T patent/DE69427862T2/de not_active Expired - Fee Related
- 1994-09-16 JP JP50937995A patent/JP3943126B2/ja not_active Expired - Fee Related
- 1994-09-16 CA CA002171561A patent/CA2171561C/en not_active Expired - Fee Related
- 1994-09-16 AU AU78363/94A patent/AU693480B2/en not_active Ceased
-
1996
- 1996-03-15 NO NO961087A patent/NO309228B1/no not_active IP Right Cessation
- 1996-03-15 FI FI961236A patent/FI961236A/fi unknown
-
1997
- 1997-01-08 NZ NZ314037A patent/NZ314037A/xx not_active IP Right Cessation
-
2005
- 2005-04-26 JP JP2005127746A patent/JP2005220141A/ja active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8932821B2 (en) | 2003-03-19 | 2015-01-13 | Biogen Idec Ma Inc. | NOGO receptor binding protein |
US9068992B2 (en) | 2004-06-24 | 2015-06-30 | Biogen Ma Inc. | Screening methods for identifying Sp35 antagonists |
US9066984B2 (en) | 2005-07-08 | 2015-06-30 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
JP2009544703A (ja) * | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
US8642040B2 (en) | 2006-07-24 | 2014-02-04 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
US9745375B2 (en) | 2008-07-09 | 2017-08-29 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
JP2012513447A (ja) * | 2008-12-22 | 2012-06-14 | クレアビリ ソスィエテ アノニム | インドロカルバゾール化合物のポリマー結合体の合成 |
US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
Also Published As
Publication number | Publication date |
---|---|
KR960704894A (ko) | 1996-10-09 |
WO1995007911A1 (en) | 1995-03-23 |
AU693480B2 (en) | 1998-07-02 |
NO961087D0 (no) | 1996-03-15 |
FI961236A0 (fi) | 1996-03-15 |
KR100186912B1 (ko) | 1999-05-01 |
HUT74679A (en) | 1997-01-28 |
NZ274355A (en) | 1997-03-24 |
DE69427862D1 (de) | 2001-09-06 |
EP0719268A1 (en) | 1996-07-03 |
US5516772A (en) | 1996-05-14 |
ATE203751T1 (de) | 2001-08-15 |
US5468872A (en) | 1995-11-21 |
JP2005220141A (ja) | 2005-08-18 |
NO961087L (no) | 1996-05-13 |
ES2160637T3 (es) | 2001-11-16 |
NO309228B1 (no) | 2001-01-02 |
HU9600657D0 (en) | 1996-05-28 |
FI961236A (fi) | 1996-03-15 |
AU7836394A (en) | 1995-04-03 |
CA2171561A1 (en) | 1995-03-23 |
DE69427862T2 (de) | 2002-04-11 |
HU222570B1 (hu) | 2003-08-28 |
EP0719268B1 (en) | 2001-08-01 |
JP3943126B2 (ja) | 2007-07-11 |
CA2171561C (en) | 1999-08-03 |
NZ314037A (en) | 2000-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502730A (ja) | ニューロトロフィン誘導活性を高めるK−252a誘導体 | |
DE60114215T2 (de) | Kondensierte pyrrolocarbazole gegen entzündungen | |
DE69310178T2 (de) | K-252a DERIVATE | |
DE69409641T2 (de) | Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen | |
CN102316732B (zh) | 氮杂*并[4,5-b]吲哚以及使用方法 | |
DE3750596T2 (de) | 1,2,3,3a,8,8a-Hexahydro-1,3a,8-Trimethylpyrrolo[2,3-b]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. | |
EP2062898B1 (de) | Spirocyclische Cyclohexan-Derivate | |
US9006234B2 (en) | Bridged heterocyclic compounds and methods of use | |
US7160899B2 (en) | Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease | |
WO2011019417A1 (en) | Pyrido [4, 3-b] indoles and methods of use | |
IE920327A1 (en) | Calcium channel antagonists and methodology for their¹identification | |
CN102548986A (zh) | 氨基吡咯烷酮衍生物及其用途 | |
JPH0714913B2 (ja) | 興奮性アミノ酸神経伝達物質に対する拮抗薬として有用なポリアミン | |
JP2001503397A (ja) | ニューロトロフィンアンタゴニスト組成物 | |
DE69827284T2 (de) | Funktionelle Fragmente des HIV-1 VPR Proteins und Verfahren zu ihrer Anwendung | |
WO2010142827A1 (es) | Propiedades neuroprotectoras de 5'-metiltioadenosina | |
DE60001138T2 (de) | Polycyclische Azaindolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
US20100273769A1 (en) | Composition and method for the treatment of parkinson's disease | |
JP2004523543A (ja) | 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法 | |
CN109761958A (zh) | 法舒地尔复合盐及其制备方法和用途 | |
KR20220158290A (ko) | 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법 | |
Kano et al. | Chinese medicine induces neurite outgrowth in PC12 mutant cells incapable of differentiation | |
US20080262019A1 (en) | Optical Isomers of (+) and (-)-Trans-2,3,4,4A,5,9B-Hexahydro-2,8-Dimethyl-1H-Pyrido[4,3-B] Indole | |
MX2008002807A (en) | Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one | |
JP2014101389A (ja) | 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060607 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070306 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070405 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100413 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100413 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |